About Sipple Syndrome (Multiple Endocrine Neoplasia, Type 2A)
Multiple endocrine neoplasia type 2 (MEN2) is an inherited disorder that affects the endocrine glands, which produce hormones. It is caused by a defect in the RET gene. MEN2 is characterized by the development of tumors in one or more endocrine glands, most commonly the adrenal, parathyroid, and thyroid glands.
MEN type 2A (MEN 2A) is also called Sipple Syndrome. It causes medullary thyroid cancer and benign (noncancerous) tumors of the parathyroid glands and adrenal glands. MEN2A is the most common type of MEN2.
MEN2 can be inherited in an autosomal dominant pattern, meaning that a person with the defective gene has a 50% chance of passing it on to their children. The features of MEN2 can vary within families but are relatively consistent in individuals. Prompt diagnosis and treatment are important to manage the condition and prevent complications.
The disease causes of MEN2 involves a defect in the RET gene, which leads to the development of multiple tumors in the affected individual. The specific causes of MEN2 are not well understood, but it is believed to be primarily caused by inherited genetic mutations.
The main risk factor of MEN2 is Inherited genetic mutation. MEN2 is an autosomal dominant disorder, which means that individuals with a family history of the condition have a higher risk of developing it.
It's important to note that while these risk factors may increase the likelihood of developing MEN2, not everyone with these risk factors will develop the condition. If you have concerns about your risk or if you have a family history of MEN2, it's best to consult with a healthcare professional for further evaluation and guidance.
Although MEN2 cannot be prevented due to its genetic nature, identification of the pathogenic mutations in the RET gene can enable early diagnosis of MEN2.
Symptoms of MEN2 depend on the specific endocrine glands affected. For MEN2A, the thyroid, adrenal gland, and parathyroid glands are affected. Symptoms may include:
- Diarrhea: This is a common symptom for MEN2.
- Thyroid Cancer: Medullary thyroid carcinoma (MTC) is the most common sign of MEN2. It is a form of thyroid cancer that can develop in individuals with this condition. Symptoms of medullary thyroid cancer include lumps in the neck, trouble swallowing, trouble breathing, and hoarseness.
- Adrenal Gland Tumor: Some people with MEN2 may develop a tumor called pheochromocytoma in the adrenal gland. This tumor can cause dangerously high blood pressure. Symptoms of pheochromocytoma include high blood pressure and rapid heart rate.
- Hyperparathyroidism: In MEN2 subtype 2A, hyperparathyroidism can occur. It disrupts the normal balance of calcium in the blood and may lead to kidney stones, thinning of bones, weakness, and fatigue. Symptoms of hyperparathyroidism include muscle and joint pain, constipation, and memory problems.,
It's important to note that symptoms can vary between individuals and within families. If you suspect you may have MEN2 or are experiencing any concerning symptoms, it's crucial to consult with a healthcare professional for an accurate diagnosis and appropriate management.
To diagnose MEN2, the following examinations, tests, and procedures are commonly performed:
- Physical exam: The doctor checks the body for signs of a problem, like pain, swelling, or unusual lumps.
- Lab tests: Blood tests check for substances linked to MEN2, such as high levels of certain stress hormones (catecholamines, epinephrine, norepinephrine, and vanillylmandelic acid). They may also test for too much calcium in the blood (hypercalcemia) or urine (hypercalciuria).
- Genetic testing: A sample of blood, saliva, or tissue is tested for gene changes linked to MEN2. This helps confirm or rule out the disease.
To determine the stage or severity of MEN2, additional examinations and tests may include:
- Imaging scans: X-rays, MRIs, or other scans help doctors see inside the body to find tumors or other signs of disease.
- More genetic testing: If initial genetic tests don’t find a problem but doctors still suspect MEN2, they may test different parts of the gene. They also check for specific markers in the blood or urine (such as calcitonin, metanephrine, and parathyroid hormone) to assess risk and predict how the disease may progress.
It's important to follow up with your healthcare provider if any symptoms worsen or change after the initial physical exam. They can provide personalized recommendations based on your individual situation.
The goals of treatment for MEN2 are to effectively manage the condition and improve clinical outcomes. Treatment is dependent on the specific endocrine glands affected by MEN2. Here are the recommended treatments and how they work to achieve these goals:
- Medullary thyroid cancer is often treated with surgery to remove the thyroid gland. After the thyroid gland is removed, people will need to take thyroid replacement medication. In some cases, radiation therapy, chemotherapy, or targeted therapy may be used.
- Hyperparathyroidism is often treated with surgery to remove the affected parathyroid glands. People usually have four parathryoid glands. Only the enlarged glands are removed.
- Pheochromocytoma from adrenal tumor is often treated with surgery to remove one or both adrenal glands. Medications may also be used to help control elevated blood pressure or rapid heart rate from pheochromocytoma.
- Psychological support: Psychological support is important for patients with MEN2 to promote comprehensive management of symptoms and improve overall well-being.
Additional treatments may be recommended based upon symptoms. Consult with a healthcare provider for a treatment plan specific to individual factors.
Medication dosing may be affected by many factors. Check with your health care professional about dosing for your individual situation. Side effects can occur. Check with your health care professional or read the information provided with your medication for additional side effect information.